Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=-program_reference_codes
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_reference_codes", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-program_reference_codes", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=-program_reference_codes", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-program_reference_codes" }, "data": [ { "type": "Grant", "id": "10694", "attributes": { "award_id": "1IK2HX003427-01A2", "title": "Provision of high quality telemental health care during COVID-19 and beyond", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2027-09-30", "award_amount": null, "principal_investigator": { "id": 26751, "first_name": "Samantha L", "last_name": "Connolly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1521, "ror": "", "name": "VA BOSTON HEALTH CARE SYSTEM", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Telemental health (TMH) via videoconferencing or phone can increase Veterans’ access to mental health (MH) care. TMH can eliminate barriers including travel distance and cost, as well as physical limitations, caregiving responsibilities, and MH symptoms that can make leaving home difficult. Prior to COVID- 19, rates of TMH in VA were low (~9%). There was a dramatic shift towards TMH during COVID-19 to prevent infection, with ~50% of care delivered by phone, ~25% by video, and ~25% in-person. Benefits and drawbacks of phone, video, and in-person care must be considered when choosing a MH care modality. If patients, providers, and/or leadership believe that phone care is equivalent in quality to video and/or in-person, they may be more likely to choose this modality as it often has the fewest barriers to use; however, based on limited evidence, phone care may be lower quality than video and in-person. We need more nuanced analyses regarding: 1) the relative quality of phone, video, and in-person care (e.g., for more complex patients, for psychotherapy sessions versus shorter medication management appointments), and 2) patient preferences. As a clinical psychologist and HSR&D investigator with TMH experience, I am well-positioned to conduct this research. This proposal will provide key methodological training and advance me toward my goal of becoming a leading health services researcher and implementation scientist with expertise in telehealth. Significance/Impact: MH, telehealth, access, and quality of care are all major HSR&D research priorities. The increased use of TMH during COVID-19 has led to a wealth of untapped data through which we can examine the relative quality of TMH care as well as patient preferences across modalities, in order to improve care modality decision-making processes. Results, which will incorporate data from millions of patients and thousands of providers, have the potential to impact delivery of high-quality MH care on a national scale. Innovation: To our knowledge, there has been no published research that: 1) compares the quality and patient preference of phone, video, and in-person MH care, and 2) uses this information to develop and implement evidenced-based strategies to increase video use when clinically effective and preferred by patients. Specific Aims: Aim 1: Examine quality outcomes of phone, video, and in-person MH care (e.g., differences in MH hospitalization rates). Hypothesis: Video care will be equivalent to in-person care and superior to phone care for more complex patients (e.g., history of MH hospitalization, 3+ MH diagnoses) and for psychotherapy appointments. Aim 2: Qualitative interviews with MH patients, providers, and leadership. Research question: What are facilitators/barriers to video use based on stakeholder attitudes, preferences, and decision-making processes, and how do these factors vary between sites with high levels of phone, video, and in-person care? Aim 3: Develop/pilot implementation strategies to increase video use in circumstances where it is clinically effective and preferred by patients. Hypothesis: Implementation strategies will increase video use. Methodology: In Aim 1, I will test for differences in quality outcomes between modalities via a sample of ~2 million Veterans who received MH care between 3/2020-3/2021 using comparative effectiveness research strategies. In Aim 2, I will conduct interviews with key stakeholders to understand facilitators and barriers to video use based on attitudes, preferences and current decision-making processes. In Aim 3, I will synthesize Aim 1 and 2 findings to develop and pilot implementation strategies at one VISN 1 MH site to increase video use in circumstances where it is clinically effective and preferred by patients. Strategies will be targeted at the patient, provider, and/or system levels based on Aim 1 and 2 findings. Next Steps/Implementation: The piloted strategies will be spread to additional MH sites, and ultimately other clinical services, via hybrid implementation-effectiveness trials in subsequent IIRs. Findings will be communicated to MH and Connected Care operational partners to inform the future of VA MH care delivery.", "keywords": [ "Academy", "Address", "Anxiety", "Appointment", "Attitude", "COVID-19", "COVID-19 pandemic", "Caring", "Clinic", "Clinical", "Clinical Services", "Collaborations", "Comparative Effectiveness Research", "Complex", "Data", "Decision Making", "Development", "Diagnosis", "Effectiveness", "Ensure", "Future", "Goals", "Health Services", "Health Services Accessibility", "Health Technology", "Healthcare", "Home", "Hospitalization", "Hybrids", "Infection", "Infection prevention", "Interview", "Leadership", "Medication Management", "Medicine", "Mental Health", "Mental Health Services", "Mentors", "Methodology", "Methods", "Modality", "Outcome", "Outpatients", "Patient Care", "Patient Preferences", "Patients", "Persons", "Positioning Attribute", "Process", "Provider", "Psychologist", "Psychotherapy", "Publishing", "Quality of Care", "Recording of previous events", "Research", "Research Personnel", "Research Priority", "Safety", "Sampling", "Scientist", "Services", "Site", "Suicide prevention", "Symptoms", "System", "Telemental", "Telephone", "Testing", "Time", "Training", "Travel", "Veterans", "Videoconferencing", "Work", "authority", "base", "caregiving", "comparative effectiveness", "connected care", "coronavirus disease", "cost", "design", "effectiveness implementation study", "effectiveness implementation trial", "effectiveness trial", "evidence base", "experience", "health care delivery", "hospitalization rates", "implementation strategy", "improved", "infection risk", "innovation", "pandemic disease", "preference", "prevent", "primary care services", "social stigma", "telehealth" ], "approved": true } }, { "type": "Grant", "id": "10695", "attributes": { "award_id": "1I21RX004092-01A1", "title": "Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2024-09-30", "award_amount": null, "principal_investigator": { "id": 26752, "first_name": "Marianne", "last_name": "Goodman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1533, "ror": "", "name": "JAMES J PETERS VA MEDICAL CENTER", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "At present, 34.6 million people in the United States, and 273,232 Veterans tested or treated in Veteran Affairs facilities contracted COVID-19. While the exact prevalence of Post-Acute COVID-19 Syndrome (PACS) among Veterans is unknown, estimates of psychiatric/neurological PACS using a large global sample of COVID-19 patients (N=236,379) suggest a prevalence of approximately 11,390,400 Americans, and 90,311 Veterans in VA care, with rates likely to increase over time. Moreover, large scale studies suggest up to 35% of individuals experience functional impairment 8 months after COVID-19, and high prevalence of post-infection mental illness including anxiety disorders, depression, and post-traumatic stress disorder. Using longitudinal data from our academic affiliate, Icahn School of Medicine at Mount Sinai’s COVID registry (n≈1200), and local James J. Peters VA’s Clinical PACS program, coupled with our expertise in recovery-based psychotherapy, we are uniquely poised to develop an innovative treatment for Veterans struggling with PACS. Our intervention aims to improve psychological adjustment to PACS symptoms, promote resiliency, and facilitate coping, all of which can impact functional status and quality of life. The PACS-Coping and Recovery (PACS-CR) intervention we aim to develop focuses on psychological adjustment and coping, and augments medical, rehabilitative and neurological treatment for this population. Our approach is based on the CHIME model of personal recovery which includes five overarching processes: 1) Connectedness; 2) Hope and optimism about the future; 3) Identity; 4) Meaning in life; and 5) Empowerment. We will target the CHIME processes using established psychotherapeutic techniques such as skills training, acceptance-based and identity-based principles. Based on adaptations from existing recovery-based and COVID-19 distress group interventions that our team has developed and piloted, we are proposing a treatment framework that consists of a core of twelve 90-minutes sessions (1x/week x 12 weeks) with additional weekly sessions on specialized topics that are optional. We are proposing a treatment development NIH Stage 1A study to develop a Post-Acute COVID-19 Syndrome psychotherapeutic intervention, “PACS Coping and Recovery” (PACS-CR) through an iterative development process while collecting pilot data to assess its acceptability and feasibility. Our treatment development SPiRE will focus on 1) determining the treatment needs of Veterans with PACS, 2) developing the treatment using pilot qualitative data and aided by stakeholder feedback, 3) refining the intervention by three iterative pilots of our groups, testing both in person and telehealth versions. Pre and post measures will be utilized to track functional improvement and the degree to which this recovery-focused intervention has enabled the veterans to engage in meaningful life changes.", "keywords": [ "Activities of Daily Living", "Acute", "Address", "American", "Anxiety", "Anxiety Disorders", "Arthralgia", "COVID-19", "COVID-19 patient", "Cardiovascular system", "Caring", "Chronic", "Climacteric", "Clinical", "Consultations", "Contracts", "Coping Skills", "Coupled", "Data", "Development", "Disease", "Distress", "Education", "Employment", "Epidemiology", "Fatigue", "Feedback", "Fostering", "Future", "Goals", "Headache", "Health", "High Prevalence", "Impairment", "Individual", "Infection", "Intervention", "Interview", "Knowledge", "Leadership", "Life", "Life Style", "Loneliness", "Long COVID", "Longitudinal Studies", "Measures", "Medical", "Memory impairment", "Mental Depression", "Mental Health", "Mental disorders", "Modeling", "Needs Assessment", "Neurologic", "Neurologic Symptoms", "Nutritionist", "Pain", "Pain Disorder", "Participant", "Patients", "Persons", "Phase", "Population", "Post-Traumatic Stress Disorders", "Prevalence", "Process", "Protocols documentation", "Provider", "Psychological adjustment", "Psychotherapy", "Quality of life", "Recovery", "Registries", "Rehabilitation therapy", "Sampling", "Services", "Sleep Disorders", "Sleeplessness", "Specialist", "Symptoms", "Techniques", "Testing", "Time", "United States", "United States Department of Veterans Affairs", "United States National Institutes of Health", "Veterans", "acceptability and feasibility", "arm", "base", "cohort", "common symptom", "coping", "coronavirus disease", "design", "disorder later incidence prevention", "empowerment", "experience", "fitness", "flexibility", "follow-up", "functional disability", "functional improvement", "functional status", "group intervention", "health assessment", "improved", "innovation", "interdisciplinary approach", "medical schools", "neurological rehabilitation", "novel", "optimism", "physical conditioning", "post SARS-CoV-2 infection", "programs", "psychosocial", "pulmonary symptom", "rehabilitation strategy", "resilience", "satisfaction", "skills", "skills training", "sleep health", "symptomatology", "telehealth", "therapy development" ], "approved": true } }, { "type": "Grant", "id": "10696", "attributes": { "award_id": "1I01RX003656-01A2", "title": "INDIVIDUAL PLACEMENT AND SUPPORT FOR VETERANS WITH OPIOID USE DISORDER: A MIXED METHODS STUDY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2026-09-30", "award_amount": null, "principal_investigator": { "id": 25523, "first_name": "LORI L.", "last_name": "DAVIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 24118, "first_name": "Mercy N", "last_name": "Mumba", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1699, "ror": "", "name": "TUSCALOOSA VETERANS AFFAIRS MEDICAL CTR", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 1699, "ror": "", "name": "TUSCALOOSA VETERANS AFFAIRS MEDICAL CTR", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Living with an opioid use disorder (OUD) can make finding and sustaining employment a significant challenge and is only getting worse in the COVID-19 environment. With states reporting unemployment rates as high as 15-20%, the negative effects of unemployment on OUD treatment outcomes are expected to deteriorate. The COVID-19 pandemic has further resulted in treatment disruptions that are exacerbating poor outcomes, because of unemployment, social isolation, interrupted access to medication for OUD treatment (MOUD), and interference of daily routines that provide the necessary structure for many people with OUD. Our group has conducted research that shows Individual Placement and Support (IPS) is efficacious in yielding more weeks worked and higher steady employment rates for Veterans with posttraumatic stress disorder and Veterans diagnosed with a broad range of mental conditions (including substance use) being treated in a primary care setting; however, little is known about its efficacy in Veterans with OUD. Only one small study in civilians (n=45) with OUD has been conducted, in which 50% of the participants assigned to IPS gained employment compared to 5% of waitlist control at 6 months follow-up (p<0.001). A systematic review of effectiveness of IPS with conditions other than serious psychiatric mental illness revealed major limitations in many studies, including small sample sizes, major modifications to IPS model, weak control, and short follow-up periods. A larger randomized controlled trial of IPS for Veterans recovering from OUD with longer follow-up period, strong treatment control, and strict adherence to IPS fidelity, such as the one we propose, is warranted. Methods: This is a prospective, multi-site, randomized controlled trial to determine the efficacy of IPS compared to non-IPS Treatment-as-Usual Vocational Rehabilitation (TAU-VR) in a sample of 120 Veterans recovering from OUD (Aim 1). Investigators hypothesize that Veterans with OUD randomized to IPS will work significantly more weeks in a competitive job over 15 months compared to the non-IPS TAU-VR group. Additionally, compared to non-IPS TAU-VR, IPS recipients will earn significantly more income from competitive jobs and be significantly more likely to achieve steady employment. The investigators will also evaluate self-report measures of resilience, quality of life, perceived stress, community engagement, depression, anxiety, abstinence self-efficacy and suicide risk. As Aim 2, using a Community Based Participatory Research (CBRP) approach, the investigators will identify the contextual barriers to and facilitators of implementing vocational services for Veterans in both the IPS and non-IPS TAU-VR study arms, including evaluation of employment challenges, optimal occupational functioning, and OUD treatment adherence, with specific emphasis on the impact of COVID-19 and social distancing. To address Aim 2, the investigators will conduct semi-structured interviews with Veterans with OUD randomized to IPS or non-IPS TAU-VR. These interviews will be supplemented by qualitative findings from an ongoing Rehabilitation R&D pilot study that includes qualitative interviews on the same topic with IPS specialists, providers, unemployed veterans with OUD, and potential employers. Working with a CBPR Steering Committee, findings will be aggregated to reach consensus on best practices for IPS implementation in this new population. In an Exploratory Aim 3, the impact of IPS will be compared to non-IPS TAU-VR on participants’ adherence to MOUD and rates of OUD relapse. Significance: This study seeks to find the best intervention for successful recovery and functional reintegration for Veterans recovering from OUD. This study is especially timely given the societal impact of the COVID-19 pandemic on employment and mental health problems of the general population, and Veterans specifically. Additionally, with the new VHA plan to expand supported employment services to Veterans with substance use disorders in the coming years, our study is timely and can significantly contribute to the evidence required to successfully implement and sustain supported employment services in this new priority population.", "keywords": [ "Abstinence", "Address", "Adherence", "Anxiety", "Area", "Back", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 pandemic effects", "Communities", "Consensus", "Control Groups", "Data", "Diagnosis", "Economic Burden", "Economics", "Effectiveness", "Employment", "Environment", "Evaluation", "Feeling hopeless", "Foundations", "General Population", "Goals", "Homelessness", "Income", "Individual", "Interruption", "Intervention", "Interview", "Link", "Measures", "Mental Depression", "Mental Health", "Mental disorders", "Methods", "Modeling", "Modification", "Occupational", "Occupations", "Outcome", "Participant", "Patient Self-Report", "Persons", "Pharmaceutical Preparations", "Pilot Projects", "Population", "Post-Traumatic Stress Disorders", "Poverty", "Prevention", "Process", "Provider", "Psyche structure", "Public Health", "Publishing", "Quality of life", "Randomized", "Randomized Controlled Trials", "Recovery", "Rehabilitation therapy", "Relapse", "Reporting", "Research", "Research Personnel", "Research Support", "Resources", "Sample Size", "Sampling", "Self Efficacy", "Services", "Site", "Social Distance", "Social isolation", "Socialization", "Specialist", "Structure", "Substance Use Disorder", "Supported Employment", "Symptoms", "Time", "Treatment outcome", "Unemployment", "Veterans", "Vocational rehabilitation", "Waiting Lists", "Work", "arm", "community based participatory research", "community engagement", "design", "disorder later incidence prevention", "effectiveness evaluation", "efficacy evaluation", "efficacy testing", "evidence base", "experience", "follow-up", "functional independence", "implementation evaluation", "implementation facilitators", "improved", "interest", "methadone treatment", "opioid epidemic", "opioid use disorder", "patient population", "perceived stress", "prevent", "primary care setting", "prospective", "rehabilitation service", "research and development", "resilience", "rural area", "substance use", "success", "suicidal risk", "systematic review", "treatment adherence", "treatment as usual" ], "approved": true } }, { "type": "Grant", "id": "10697", "attributes": { "award_id": "1I01RX003639-01A2", "title": "Home-Based Exercise Tele-Rehabilitation in High-Risk Veterans: Impact of COVID-19 Exposure and Socioeconomic Factors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2026-09-30", "award_amount": null, "principal_investigator": { "id": 26753, "first_name": "KRISANN K", "last_name": "OURSLER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26754, "first_name": "ALICE S.", "last_name": "RYAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1532, "ror": "https://ror.org/036a0e562", "name": "Baltimore VA Medical Center", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "10698", "attributes": { "award_id": "1U01MD018310-01", "title": "Faithful Response II: COVID-19 Rapid Test-to-Treat with African American Churches", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6025, "first_name": "Crystal", "last_name": "Barksdale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 1016780, "principal_investigator": { "id": 6100, "first_name": "Jannette Yvonne", "last_name": "Berkley-Patton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 753, "ror": "", "name": "UNIVERSITY OF MISSOURI KANSAS CITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 753, "ror": "", "name": "UNIVERSITY OF MISSOURI KANSAS CITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "10699", "attributes": { "award_id": "1U01MD018313-01", "title": "Increasing representation of Black communities in COVID-19 home testing and surveillance data", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6121, "first_name": "Priscah", "last_name": "Mujuru", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 570231, "principal_investigator": { "id": 22449, "first_name": "Heather", "last_name": "Bradley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 964, "ror": "https://ror.org/03qt6ba18", "name": "Georgia State University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 26755, "first_name": "Natasha F", "last_name": "De Veauuse Brown", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "10700", "attributes": { "award_id": "75N93021D00035-0-759302200002-1", "title": "Completion of ACTIV-2 Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-11-06", "end_date": "2024-10-31", "award_amount": 82531927, "principal_investigator": { "id": 26756, "first_name": "ANGEE", "last_name": "GREER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1807, "ror": "", "name": "PPD, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support, NIAID serves as the sponsor for the COVID-19 clinical trial entitled “A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)” also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.", "keywords": [ "COVID-19", "COVID-19 therapeutics", "Clinical Research", "Clinical Trials", "Disease Progression", "Immune response", "Infrastructure", "Investigation", "National Institute of Allergy and Infectious Disease", "Outpatients", "Pharmacy facility", "Reporting", "SARS-CoV-2 infection", "Safety", "Services", "Support Contracts", "Therapeutic Intervention", "Viral", "coronavirus disease", "novel therapeutics", "research study", "therapeutic vaccine", "treatment trial" ], "approved": true } }, { "type": "Grant", "id": "10701", "attributes": { "award_id": "1U01MD018308-01", "title": "CO-CREATE-Ex: Community-engaged Optimization of COVID-19 Rapid Evaluation And TEsting Experiences", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6025, "first_name": "Crystal", "last_name": "Barksdale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 1023111, "principal_investigator": { "id": 23572, "first_name": "LOUISE CHANG", "last_name": "LAURENT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26718, "first_name": "Adrienn Borsika BORSIKA", "last_name": "Rabin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26719, "first_name": "Nicole A", "last_name": "Stadnick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "10702", "attributes": { "award_id": "5P20GM109091-09", "title": "Synthesis of cannabidiol dimers as potential agents to treat neurological disorders", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 6278, "first_name": "FEDERICO", "last_name": "Bernal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-08", "end_date": "2024-04-30", "award_amount": 223500, "principal_investigator": { "id": 26757, "first_name": "Francisco", "last_name": "Leon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID pandemic has worsened stress, anxiety, and depression in the US population. Current FDA approved therapeutics for these ailments are only effective in subpopulations, and it is very common for patients to have to attempt multiple regimens to find one that works. Not surprisingly, patients continue seeking alternative remedies for self-treatment, e.g., cannabis. However, regardless of the legalization of cannabis in many states and its widespread usage for these purposes, cannabis is a diverse mixture of hundreds of compounds that widely vary in amount depending on the cannabis source. One active component of cannabis, cannabidiol (CBD), has been individually studied for its medicinal activity. Epidiolex®, a highly purified form of CBD, is FDA approved to treat rare forms of epilepsy. The issue is that CBD – in its natural form – is a non-specific (poly-pharmacological) agent. CBD weakly activates several receptors of the following classes: cannabinoid, opioid, serotonin (5-HT1A, 5-HT2A), orphan-GPR55, adenosine, and TRP receptors, among others. It remains unclear which receptor(s) and signaling pathway(s) are crucial for the positive benefits of CBD. Our long-term goal is to identify and expand novel therapeutics with defined, specific mechanisms of action for neurological/mental disorders. In this light, the overall objective in this application is to create novel CBD dimers that are proposed to be specific to cannabinoid or serotonin receptors. We will assess the hypothesis that CBD homo/heterodimers will enhance the selective binding to cannabinoid and serotonin receptors through bivalent or bitopic binding on dimerreceptors or a single receptor on two sites, respectively. Upon generation of our CBD homo/heterodimer library, we will evaluate their selectivity for the above receptors, and we will also evaluate dimers in a psychoactive receptor panel (NIMH-PDSP). This will position us to build key preliminary data for a competitive NIH application. Development of these novel dimers as chemical biology probes will elucidate the interactions of CBD with serotonin and cannabinoid receptors and the structural details behind these activities. Ultimately, these CBD semisynthetic derivatives have the potential to yield favorable therapeutic indices for the treatment of stress, anxiety, and depression. Results consistent with our hypothesis will have wide-ranging public health implications because of societal interest in CBD despite its poorly understood activities and because of the urgent need for safe, effective therapies. Importantly, if successful, the long-term goal is to move promising compounds into advanced preclinical testing.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10703", "attributes": { "award_id": "1U01MD018320-01", "title": "Project IMPROVE: Implementing Community-Engaged Intervention Research to Increase Rapid SARS-CoV-2 Self-Testing Among Diverse Underserved and Vulnerable Asian Americans", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6025, "first_name": "Crystal", "last_name": "Barksdale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 1140263, "principal_investigator": { "id": 26758, "first_name": "Carolyn Y", "last_name": "Fang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26647, "first_name": "GRACE X.", "last_name": "MA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1445, "ror": "", "name": "TEMPLE UNIV OF THE COMMONWEALTH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1442, "count": 14420 } } }